- Home
- ECVT vs TRVI Comparison
ECVT vs TRVI Comparison
Compare ECVT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECVT | TRVI |
|---|---|---|
| Founded | 1935 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ECVT | TRVI |
|---|---|---|
| Price | $12.97 | $14.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $14.00 | ★ $21.55 |
| AVG Volume (30 Days) | ★ 1.7M | 943.9K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $723,515,000.00 | N/A |
| Revenue This Year | $29.07 | N/A |
| Revenue Next Year | $6.71 | N/A |
| P/E Ratio | $327.25 | ★ N/A |
| Revenue Growth | ★ 2.70 | N/A |
| 52 Week Low | $7.39 | $5.41 |
| 52 Week High | $15.09 | $16.12 |
Technical Indicators
Market Signals| Indicator | ECVT | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 57.24 |
| Support Level | $12.74 | $10.07 |
| Resistance Level | $15.01 | $14.57 |
| Average True Range (ATR) | 0.33 | 0.60 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 34.04 | 76.35 |
Price Performance
Historical ComparisonAbout ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has one operating segment. The Company's single reportable segment, Ecoservices, derives its revenue through the sale of virgin and regenerated sulfuric acid products and services.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.